- Home
- GES vs ABUS Comparison
GES vs ABUS Comparison
Compare GES & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GES
- ABUS
- Stock Information
- Founded
- GES 1981
- ABUS 2005
- Country
- GES Switzerland
- ABUS United States
- Employees
- GES N/A
- ABUS N/A
- Industry
- GES Apparel
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- GES Consumer Discretionary
- ABUS Health Care
- Exchange
- GES Nasdaq
- ABUS Nasdaq
- Market Cap
- GES 879.0M
- ABUS 711.2M
- IPO Year
- GES 1996
- ABUS N/A
- Fundamental
- Price
- GES $16.70
- ABUS $4.43
- Analyst Decision
- GES Buy
- ABUS Strong Buy
- Analyst Count
- GES 5
- ABUS 2
- Target Price
- GES $19.25
- ABUS $5.00
- AVG Volume (30 Days)
- GES 1.6M
- ABUS 1.6M
- Earning Date
- GES 08-27-2025
- ABUS 11-05-2025
- Dividend Yield
- GES 5.38%
- ABUS N/A
- EPS Growth
- GES N/A
- ABUS N/A
- EPS
- GES 0.35
- ABUS N/A
- Revenue
- GES $3,091,508,000.00
- ABUS $15,416,000.00
- Revenue This Year
- GES $7.67
- ABUS $138.02
- Revenue Next Year
- GES $3.32
- ABUS N/A
- P/E Ratio
- GES $48.20
- ABUS N/A
- Revenue Growth
- GES 7.84
- ABUS 53.23
- 52 Week Low
- GES $8.48
- ABUS $2.71
- 52 Week High
- GES $20.33
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- GES 67.52
- ABUS 63.83
- Support Level
- GES $16.67
- ABUS $4.37
- Resistance Level
- GES $16.76
- ABUS $5.10
- Average True Range (ATR)
- GES 0.08
- ABUS 0.26
- MACD
- GES -0.14
- ABUS 0.03
- Stochastic Oscillator
- GES 20.00
- ABUS 55.33
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.